Inhibikase Therapeutics, Inc.
NASDAQTotal Valuation
Inhibikase Therapeutics, Inc. carries a market capitalization of 330.08M, placing it among publicly traded companies globally. Its enterprise value stands at 51.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 330.08M |
| Enterprise Value | 51.45M |
Share Statistics
Inhibikase Therapeutics, Inc. currently has 132.03M shares outstanding.
| Shares Outstanding | 132.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | -5.52 |
| P/OCF Ratio | -5.52 |
Financial Position
Inhibikase Therapeutics, Inc. maintains a current ratio of 30.14, meaning it holds 30.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 30.14 |
| Quick Ratio | 29.83 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -40.23 |
| Return on Assets (ROA) | -38.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Inhibikase Therapeutics, Inc.'s stock has gained approximately 46.19883% over the past 52 weeks. The 50-day moving average sits at 2.26, while the 200-day moving average is 1.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | 46.19883% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 1.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -55.75M, while operating income came in at -55.80M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -55.80M |
| Pretax Income | -50.96M |
| Net Income | -50.96M |
| EBITDA | -55.75M |
| EBIT | -55.80M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
Total book value stands at 167.62M, with working capital of 166.46M providing operational flexibility.
| Cash & Cash Equivalents | 170.37M |
| Total Debt | N/A |
| Net Debt | -49.57M |
| Equity (Book Value) | 167.62M |
| Book Value Per Share | 1.27 |
| Working Capital | 166.46M |
Cash Flow
Inhibikase Therapeutics, Inc. produced -35.74M in operating cash flow over the past twelve months.
| Operating Cash Flow | -35.74M |
| Capital Expenditures | N/A |
| Free Cash Flow | -35.74M |
| FCF Per Share | -0.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -50.20 |
| FCF Yield | -18.11 |
Stock Splits
Inhibikase Therapeutics, Inc.'s most recent stock split took place on June 30, 2023 with a 6:1 split ratio.
| Last Split Date | 6/30/2023 |
| Split Ratio | 6:1 |
Scores
Inhibikase Therapeutics, Inc. posts an Altman Z-Score of 22.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.11 |